Recent developments in prostate cancer biomarker research: Therapeutic implications

British Journal of Clinical Pharmacology

Volumn 71, Issue 2, 2011, Pages 157-174

  Detchokul, Sujitra ^a   Frauman, Albert G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Biomarker; Prostate cancer; Review

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; ANTINEOPLASTIC AGENT; BELINOSTAT; BEVACIZUMAB; BIOLOGICAL MARKER; CANCER ANTIBODY; CANCER VACCINE; CV 9103; DOCETAXEL; EVEROLIMUS; GOSSYPOL ACETIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMATINIB; ISOTRETINOIN; MLN 2704; OBLIMERSEN; PANOBINOSTAT; PROSTATE SPECIFIC ANTIGEN; RNACTIVE; ROMIDEPSIN; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANTIANGIOGENIC GENE THERAPY; ARTICLE; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RESEARCH; CANCER SCREENING; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DIARRHEA; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EPIGENETICS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEMATURIA; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RASH; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; MASS SCREENING; MICE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650981231     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03766.x     Document Type: Article

References (167)

1. Schulz WA, Burchardt M, Cronauer MV. Molecular biology of prostate cancer. Mol Hum Reprod 2003; 9: 437-48.
2. Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol 2003; 170: 2444-52.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
4. Hayat MJ, Howlader N, Reichman E, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program. Oncologist 2007; 12: 20-37.
5. Parkes C, Wald NJ, Murphy P, George L, Watt HC, Kirby R, Knekt P, Helzlsouer KJ, Tuomilehto J. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ 1995; 311: 1340-3.
6. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005; 58: 673-84.
7. Shah JB, Reese AC, McKiernan JM, Benson MC. PSA updated: still relevant in the new millennium? Eur Urol 2005; 47: 427-32.
8. Hernandez J, Thomson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004; 101: 894-904.
9. Coldman AJ, Phillips N, Pickles TA. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ 2003; 168: 31-5.
10. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. preventive services task force. Ann Intern Med 2002; 137: 917-29.
11. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Keplan RS. Cancer surveillance series: interpreting trends in prostate cancer- Part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 1017-24.
12. Vis AN. Does PSA screening reduce prostate cancer mortality? CMAJ 2002; 166: 600-1.
13. Andriole GL, Crawford D, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9.
14. Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
15. Gann PH, Chatterton RT, Lee C. Peptide growth factors as biomarkers of prostate cancer risk. Epidemiol Rev 2001; 23: 67-71.
16. Golias C, Charalabopoulos A, Stagikas D, Giannakopoulos X, Pescho D, Batistatou A, Sofikitis N, Charalabopoulos K. Molecular profiling and genomic microarrays in prostate cancer. Exp Oncol 2007; 29: 82-4.
17. Gimba ERP, Barcinski MA. Molecular aspects of prostate cancer: implications for future directions. Int Braz J Urol 2003; 29: 401-11.
18. Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, Gwyther S, Eisenhauer EA. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 2009; 45: 261-7.
19. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95: 1735-40.
20. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000; 14: 2410-34.
21. Nelson EC, Cambio AJ, Yang JC, Ok J-H, Lara JPN, Evans CP. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis 2007; 10: 6-14.
22. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Scarpa RM, Angeli A, Dogliptti L. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005; 12: 109-17.
23. Arlen PM, Gulley JL. Current perspectives in prostate cancer vaccines. Anticancer Agents Med Chem 2009; 9: 1052-7.
24. Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX (TM) vaccine for prostate cancer. Urol Oncol 2006; 24: 419-24.
25. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol 1999; 17: 1047-60.
26. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor-cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43.
27. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894-903.
28. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 2006; 25: 321-52.
29. Morrissey PJ, Bressler L, Park LS, Alpert A, Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody-response by enhancing the function of antigen-presenting cells. J Immunol 1987; 139: 1113-19.
30. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1260-9.
31. Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S, Bastian A, Marte J, Tsang KY, Beetham P, Grosenbach DW, Schlom J, Dahut W. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005; 174: 539-46.
32. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59: 5160-8.
33. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008; 113: 975-84.
34. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 2006; 12: 3394-401.
35. Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol 2008; 180: 2011-17.
36. ClinicalTrials.gov. Biological therapy in treating patients with prostate cancer. ClinicalTrials.gov; 1999; Available at (last accessed 20 August 2010).
37. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol Lett 2008; 115: 33-42.
38. ClinicalTrials.gov. RNActive®-derived therapeutic vaccine. ClinicalTrials.gov; 2009; Available at (last accessed 20 August 2010).
39. ClinicalTrials.gov. Safety and efficacy trial of a RNActive®-derived prostate cancer vaccine in hormone refractory disease. ClinicalTrials.gov; 2009; Available at (last accessed 20 August 2010).
40. Brill TH, Kubler HR, Pohla H, Buchner A, Fend F, Schuster T, van Randenborgh H, Paul R, Kummer T, Plank C, Eisele B, Breul J, Hartung R, Schendel DJ, Gansbacher B. Therapeutic vaccination with an Interleukin-2-Interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum Gene Ther 2009; 20: 1641-51.
41. Brill TH, Kubler HR, von Randenborgh H, Fend F, Pohla H, Breul J, Hartung R, Paul R, Schendel DJ, Gansbacher B. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer - a phase I clinical trial. J Gene Med 2007; 9: 547-60.
42. Nasu Y, Bangma CH, Hull GW, Lee H-M, Hu J, Wang J, McCurdy MA, Shimura S, Yang G, Timme TL, Thompson TC. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther 1999; 6: 338-49.
43. Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Frolov A, Brenner MK, Kadmon D, Thompson TC. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther 2007; 14: 819-27.
44. Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 2006; 13: 253-65.
45. Nikitina EY, Desai SA, Zhao XQ, Song WT, Luo AZ, Gangula RD, Slawin KM, Spencer DM. Versatile prostate cancer treatment with inducible caspase and interleukin-12. Cancer Res 2005; 65: 4309-19.
46. Satoh T, Saika T, Ebara S, Kusaka N, Timme TL, Yang G, Wang JX, Mouraviev V, Cao GW, Fattah EMA, Thompson TC. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res 2003; 63: 7853-60.
47. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olague C, Sola J, Sadaba B, Lacasa C, Melero I, Qian C, Prieto J. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22: 1389-97.
48. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000; 6: 1678-92.
49. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-903.
50. Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD. Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 2010; 17: 360-9.
51. ClinicalTrials.gov. Gene therapy for prostate cancer that returns after radiation therapy. ClinicalTrials.gov; 2005; Available at (last accessed 20 August 2010).
52. ClinicalTrials.gov. Vaccine therapy plus interleukin-12 in treating patients with metastatic prostate cancer that has not responded to hormone therapy. ClinicalTrials.gov; 2001; Available at (last accessed 20 August 2010).
53. ClinicalTrials.gov. Vorinostat in treating patients with progressive metastatic prostate cancer. ClinicalTrials.gov; 2006; Available at (last accessed 20 August 2010).
54. ClinicalTrials.gov. Androgen deprivation therapy and vorinostat followed by radical prostatectomy in treating patients with localized prostate cancer. ClinicalTrials.gov; 2007; Available at (last accessed 20 August 2010).
55. ClinicalTrials.gov. A dose finding study with i.v. panobinostat (LBH589), docetaxel, and prednisone in patients with hormone refractory prostate cancer. ClinicalTrials.gov; 2008; Available at (last accessed 20 August 2010).
56. ClinicalTrials.gov. Efficacy and safety study of panobinostat in patients with metastatic hormone refractory prostate cancer. ClinicalTrials.gov; 2008; Available at (last accessed 20 August 2010).
57. ClinicalTrials.gov. PXD101 and isotretinoin in treating patients with solid tumors that are metastatic or that cannot be removed by surgery. ClinicalTrials.gov; 2006; Available at (last accessed 20 August 2010).
58. ClinicalTrials.gov. Valproic acid and bevacizumab in patients with advanced cancer. ClinicalTrials.gov; 2007; Available at (last accessed 20 August 2010).
59. ClinicalTrials.gov. Valproic acid in treating patients with progressive, non-metastatic prostate cancer. ClinicalTrials.gov; 2008; Available at (last accessed 20 August 2010).
60. ClinicalTrials.gov. A research study for patients with prostate cancer. ClinicalTrials.gov; 2005; Available at (last accessed 20 August 2010).
61. Kudahetti S, Fisher G, Ambroisine L, Foster C, Reuter V, Eastham J, Moller H, Kattan MW, Cooper CS, Scardino P, Cuzick J, Berney D. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU Int 2009; 104: 20-4.
62. Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Ann Intern Med 2009; 150: 595-603.
63. Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CE, Neal DE, Hamdy FC. Bcl-2 Overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996; 74: 1258-62.
64. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC, Mihatsch MJ. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996; 148: 1557-65.
65. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, Voneschenbach AC, Conti CJ. P53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85: 1657-69.
66. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923-31.
67. Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TRJ, DeBono JS. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 804-10.
68. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9: 3578-88.
69. Vaishampayan U, Rathkopf D, Chi KN, Hotte S, Vogelzang N, Alumkal J, Agrawal M, Picus J, Fandi A, Scher HI. Phase Ib dose-finding trial of intravenous (i.v.) panobinostat (PAN) with docetaxel (DOC) and prednisone (PRED) in patients (pts) with castration resistant prostate cancer (CRPC). EJC Suppl 2009; 7: 413-14.
70. Molife LR, Attard G, Fong PC, Karavasilis V, Reid AHM, Patterson S, Riggs CE, Higano C, Stadler WM, McCulloch W, Dearnaley D, Parker C, de Bono JS. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 2010; 21: 109-13.
71. Rathkopf DE, Wong BY, Ross RW, George DJ, Picus J, Atadja P, Yang W, Culver KW, Woo MM, Scher HI. A phase I study of oral panobinostat (Lbh589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (Crpc). Ann Oncol 2008; 19: 199-200.
72. Pan LN, Lu J, Huang BQ. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol 2007; 4: 337-43.
73. Kassi E, Papoutsi Z, Pratsinis H, Aligiannis N, Manoussakis M, Moutsatsou P. Ursolic acid, a naturally occurring triterpenoid, demonstrates anticancer activity on human prostate cancer cells. J Cancer Res Clin Oncol 2007; 133: 493-500.
74. Zhang Y, Kong C, Wang H, Wang L, Xu C, Sun Y. Phosphorylation of Bcl-2 and activation of caspase-3 via the c-Jun N-terminal kinase pathway in ursolic acid-induced DU145 cells apoptosis. Biochimie 2009; 91: 1173-9.
75. Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim W, Cao W, Urbanek C, Wong D, Goodison S, Rosser CJ. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 2009; 69: 1460-9.
76. Nariculam J, Freeman A, Bott S, Munson P, Cable N, Brookman-Amissah N, Williamson M, Kirby RS, Masters J, Feneley M. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of Bcl-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. Asian J Androl 2009; 11: 109-18.
77. Anderson EM, Miller P, Ilsley D, Marshall W, Khvorova A, Stein CA, Benimetskaya L. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature. Cancer Gene Ther 2006; 13: 406-14.
78. ClinicalTrials.gov. Docetaxel with or without oblimersen in treating patients with hormone-refractory adenocarcinoma (cancer) of the prostate. ClinicalTrials.gov; 2004; Available at (last accessed 20 August 2010).
79. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11: 3854-61.
80. Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, Daugaard G, Gil T, Graham J, Carpentier P, Calabro F, Collette L, Lacombe D. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20: 1264-9.
81. Patel MP, Masood A, Patel PS, Chanan-Khan AA. Targeting the Bcl-2. Curr Opin Oncol 2009; 21: 516-23.
82. ClinicalTrials.gov. A study of single-agent AT-101 in men with hormone refractory prostate cancer. ClinicalTrials.gov; 2006; Available at (last accessed 20 August 2010).
83. ClinicalTrials.gov. Safety and efficacy study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer. ClinicalTrials.gov; 2006; Available at (last accessed 20 August 2010).
84. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009; 15: 3172-6.
85. MacVicar G, Greco FA, Reeves J, Curti B, Poiesz B, Somer B, Brill K, Leopold L. An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer. In: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland. EJC Suppl 2008: 66.
86. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
87. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004; 100: 751-7.
88. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M, Sasamata M. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-21.
89. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008; 26: 5198-203.
90. ClinicalTrials.gov. An open-label study of YM155 + docetaxel in subjects with advanced hormone refractory prostate. ClinicalTrials.gov; 2007; Available at (last accessed 20 August 2010).
91. ClinicalTrials.gov. A clinical pharmacological study of YM155 after intravenous infusion in patients with advanced cancer. ClinicalTrials.gov; 2009; Available at (last accessed 20 August 2010).
92. Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010; 116: 1075-83.
93. Henry MD, Wen SH, Silva MD, Chandra S, Milton M, Worland PJ. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004; 64: 7995-8001.
94. Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, Delacruz A, Lee Y, Webb IJ, Scher HI. Phase I trial of the prostate-specific membrane antigen directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 2008; 26: 2147-54.
95. ClinicalTrials.gov. A trial of MLN2704 in subjects with metastatic androgen independent prostate cancer. ClinicalTrials.gov; 2003; Available at (last accessed 20 August 2010).
96. ClinicalTrials.gov. MLN2704 in treating patients with progressive metastatic prostate cancer. ClinicalTrials.gov; 2003; Available at (last accessed 20 August 2010).
97. ClinicalTrials.gov. MLN2704 in subjects with metastatic androgen-independent prostate cancer. ClinicalTrials.gov; 2003; Available at (last accessed 20 August 2010).
98. ClinicalTrials.gov. Radioimmunotherapy in prostate cancer using 177Lu-J591 antibody. ClinicalTrials.gov; 2007; Available at (last accessed 20 August 2010).
99. ClinicalTrials.gov. Treatment with radiolabeled monoclonal antibody HuJ591-GS (177Lu-J591) in patients with metastatic prostate cancer. ClinicalTrials.gov; 2005; Available at (last accessed 20 August 2010).
100. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of (177)lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23: 4591-601.
101. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2522-31.
102. Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000; 45: 72-9.
103. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998; 51: 161-7.
104. Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009; 280: 145-53.
105. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-43.
106. Du ZX, Fujiyama C, Chen YX, Masaki Z. Expression of hypoxia-inducible factor 1 alpha in human normal, benign, and malignant prostate tissue. Chin Med J 2003; 116: 1936-9.
107. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5.
108. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-21.
109. Kluetz PG, Figg WD, Dahut WL. Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother 2010; 11: 233-47.
110. FDA. FDA label information for bevacizumab. FDA; 2009; Available at (last accessed 20 August 2010).
111. ClinicalTrials.gov. A study to test the safety and effectiveness of docetaxel with RAD001 and bevacizumab in men with advanced prostate cancer. ClinicalTrials.gov; 2007; Available at (last accessed 20 August 2010).
112. ClinicalTrials.gov. Docetaxel, bevacizumab, thalidomide, and prednisone in treating patients with metastatic androgen-independent prostate cancer. ClinicalTrials.gov; 2004; Available at (last accessed 20 August 2010).
113. Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ. A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 800-5.
114. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, Mosberger I, Upton MP, Bubley GJ, Balk SP. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999; 155: 1271-9.
115. Fudge K, Bostwick DG, Stearns ME. Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate 1996; 29: 282-6.
116. FDA. FDA label information for Gleevec. FDA; 2003; Available at (last accessed 20 August 2010).
117. Kim SJ, Uehara H, Yazici S, Langley RR, He JQ, Tsan R, Fan D, Killion JJ, Fidler IJ. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 2004; 64: 4201-8.
118. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 2006; 98: 763-9.
119. Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology 2007; 69: 526-31.
120. Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P, DiPaola RS. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 2005; 62: 115-22.
121. ClinicalTrials.gov. Docetaxel and imatinib mesylate (Gleevec) in hormone refractory prostate cancer. ClinicalTrials.gov; 2009; Available at (last accessed 20 August 2010).
122. ClinicalTrials.gov. Docetaxel with or without imatinib mesylate in treating patients with androgen-independent prostate cancer and bone metastases. ClinicalTrials.gov; 2004; Available at (last accessed 20 August 2010).
123. ClinicalTrials.gov. A study of imatinib and docetaxel in prostate cancer. ClinicalTrials.gov; 2005; Available at (last accessed 20 August 2010).
124. Michaelson MD, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20: 913-20.
125. FDA. FDA label information for sunitinib. FDA; 2007; Available at (last accessed 20 August 2010).
126. Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, Berry WR, Zhan F, Boehm KA, Asmar L, Hutson TE. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21: 319-24.
127. ClinicalTrials.gov. Trail of Taxotere plus sunitinib on newly diagnosed, hormone refractory, metastatic prostate cancer. ClinicalTrials.gov; 2009; Available at (last accessed 20 August 2010).
128. ClinicalTrials.gov. Sunitinib malate with hormonal ablation for patients who will have prostatectomy. ClinicalTrials.gov; 2006; Available at (last accessed 20 August 2010).
129. ClinicalTrials.gov. Sunitinib malate, hormone ablation and radiation therapy in patients with prostate cancer. ClinicalTrials.gov; 2008; Available at (last accessed 20 August 2010).
130. Dai B, Kong YY, Ye DW, Ma CG, Zhou XY, Yao XD. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int 2009; 104: 1009-16.
131. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA, Nagle RB. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006; 66: 1203-12.
132. Schmitz M, Grignard G, Marguel C, Dippel W, Capesius C, Mossong J, Nathan M, Giacchi S, Scheiden R, Kieffer N. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007; 120: 1284-92.
133. Thomas GV, Horvath S, Smith BL, Crosby K, Lebel LA, Schrage M, Said J, De Kernion J, Reiter RE, Sawyers CL. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 2004; 10: 8351-6.
134. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high gleason score and advanced stage. Cancer Res 1999; 59: 4291-6.
135. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-76.
136. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601.
137. Wu LC, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65: 2825-31.
138. Xu YY, Chen SY, Ross KN, Balk SP. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res 2006; 66: 7783-92.
139. Muders MH, Zhang HY, Wang E, Tindall DJ, Datta K. Vascular endothelial growth factor-c protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Res 2009; 69: 6042-8.
140. Morgan TM, Pitts TEM, Gross TS, Poliachik SL, Vessella RL, Corey E. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 2008; 68: 861-71.
141. Amato RJ, Jac J, Mohammad T, Saxena S. Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer 2008; 6: 97-102.
142. ClinicalTrials.gov. Temsirolimus and bevacizumab in treating patients with hormone-resistant metastatic prostate cancer That did not respond to chemotherapy. ClinicalTrials.gov; 2010 [updated 12 March 2010]; Available at (last accessed 20 August 2010).
143. ClinicalTrials.gov. Everolimus as first-line therapy in treating patients with prostate cancer. ClinicalTrials.gov; 2009; Available at (last accessed 20 August 2010).
144. ClinicalTrials.gov. Impact of temsirolimus therapy on circulating tumor cell biology in men with castration resistant metastatic prostate cancer. ClinicalTrials.gov; 2009; Available at (last accessed 20 August 2010).
145. ClinicalTrials.gov. Single agent temsirolimus (Torisel®) in chemotherapy-naïve castration-resistant prostate cancer patients. ClinicalTrials.gov; 2009; Available at (last accessed 20 August 2010).
146. Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, Imbimbo C, Perdona S, Giordano A, Giuliano M, Labianca R, De Placido S. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008; 54: 1089-96.
147. ClinicalTrials.gov. Docetaxel and prednisone with or without bevacizumab in treating patients with prostate cancer that did not respond to hormone therapy. ClinicalTrials.gov; 2005; Available at (last accessed 20 August 2010).
148. ClinicalTrials.gov. Androgen deprivation therapy +/- bevacizumab for PSA recurrence of prostate cancer after definitive local therapy. ClinicalTrials.gov; 2008; Available at (last accessed 20 August 2010).
149. ClinicalTrials.gov. Study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy. ClinicalTrials.gov; 2008; Available at (last accessed 20 August 2010).
150. ClinicalTrials.gov. Bevacizumab, hormone therapy, and radiation therapy in treating patients with locally advanced prostate cancer. ClinicalTrials.gov; 2006; Available at (last accessed 20 August 2010).
151. ClinicalTrials.gov. Bevacizumab with hormonal and radiotherapy for high-risk prostate cancer. ClinicalTrials.gov; 2006; Available at (last accessed 20 August 2010).
152. ClinicalTrials.gov. Phase II study of RAD001 in a neoadjuvant setting in men with intermediate or high risk prostate cancer. ClinicalTrials.gov; 2008; Available at (last accessed 20 August 2010).
153. ClinicalTrials.gov. An open label exploratory study in newly diagnosed prostate cancer patients. ClinicalTrials.gov; 2005; Available at (last accessed 20 August 2010).
154. ClinicalTrials.gov. Dose escalation and efficacy trial of GVAX® prostate cancer vaccine. ClinicalTrials.gov; 2005; Available at (last accessed 20 August 2010).
155. ClinicalTrials.gov. Androgen ablation therapy with or without vaccine therapy in treating patients with prostate cancer. ClinicalTrials.gov; 2008; Available at (last accessed 20 August 2010).
156. ClinicalTrials.gov. Safety and efficacy studies of panobinostat and bicalutamide in patients with recurrent prostate cancer after castration. ClinicalTrials.gov; 2009; Available at (last accessed 20 August 2010).
157. ClinicalTrials.gov. Study of oral PXD101 in patients with advanced solid tumors or lymphoma. ClinicalTrials.gov; 2006; Available at (last accessed 20 August 2010).
158. ClinicalTrials.gov. Gossypol and androgen ablation therapy in treating patients with newly diagnosed metastatic prostate cancer. ClinicalTrials.gov; 2008; Available at (last accessed 20 August 2010).
159. ClinicalTrials.gov. Gossypol, paclitaxel, and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery. ClinicalTrials.gov; 2009; Available at (last accessed 20 August 2010).
160. ClinicalTrials.gov. Docetaxel/prednisone plus fractionated 177Lu- J591 antibody for metastatic, castrate-resistant prostate cancer. ClinicalTrials.gov; 2009; Available at (last accessed 20 August 2010).
161. ClinicalTrials.gov. 177Lu radiolabeled monoclonal antibody HuJ591 (177Lu-J591) and ketoconazole in patients with prostate cancer. ClinicalTrials.gov; 2009; Available at (last accessed 20 August 2010).
162. ClinicalTrials.gov. Bevacizumab in treating patients with relapsed prostate cancer that did not respond to hormone therapy. ClinicalTrials.gov; 2007; Available at (last accessed 20 August 2010).
163. ClinicalTrials.gov. Avastin, docetaxel and androgen deprivation followed by continued avastin and androgen deprivation for men with a rising PSA after local therapy. ClinicalTrials.gov; 2008; Available at (last accessed 20 August 2010).
164. ClinicalTrials.gov. Treatment of prostate cancer with adjuvant bevacizumab plus erlotinib. ClinicalTrials.gov; 2005; Available at (last accessed 20 August 2010).
165. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 2007; 13: 5816-24.
166. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 3323-9.
167. ClinicalTrials.gov. Clinical study of SU011248 in subjects with high risk prostate cancer who have elected to undergo radical prostatectomy. ClinicalTrials.gov; 2008; Available at (last accessed 20 August 2010).